IDS Intelligent Detection Systems Inc -
IDS Intelligent appoints Strachan executive chairman
IDS Intelligent Detection Systems Inc ISD
Shares issued 22,080,901 1999-10-04 close $2.85
Tuesday Oct 5 1999
Dr. Mariusz Rybak reports
IDS Intelligent Detection Systems has appointed Graham Strachan as executive chairman of Caduceon Inc., a division of IDS which specializes in leading-edge point-of-care health analysis.
"We are very fortunate to have someone of Graham's experience join us," says Dr. Rybak. "His leadership will certainly help to establish Caduceon's place in the emerging bioscience market and position it for future success."
Mr. Strachan, who has almost 20 years of experience in the Canadian bioscience industry, is widely acknowledged as a spokesperson and leader for the biotechnology industry in Canada. Most recently, he was president and chief executive officer of Allelix Biopharmaceuticals Inc. where he successfully reorganized the company and managed an initial public offering. He is also an active participant in several life science and technology-based companies.
Although Caduceon is a relatively new company, Mr. Strachan is confident about its future potential. "I have monitored the progress of this company for some time and I chose Caduceon because I have great faith in its ability to become a leader in the life sciences sector," says Mr. Strachan. "The products it has in development will have strong applications for the medical field and I am looking forward to taking these innovations to the marketplace."
Through Caduceon, IDS is adapting its core sensory technology as a non-invasive diagnostic screening platform for use in point-of-care clinical diagnostic settings and has several new products in development, including a breath analyzer, which can be used to detect organic compounds related to disease states. By removing traditional barriers to the detection process, this highly-sensitive equipment will enable physicians to gather near-real time information about patients' metabolic states, without the need for invasive arterial blood analysis. The breath analyzer will be unveiled at the upcoming Ontario Hospital Association Convention on Nov. 21 to 24, 1999.
Dr. Rybak is also pleased to announce additional new appointments to the board of directors of Caduceon including Paul Curley, president, Advance Planning & Communications Inc.; Ray Hession, president and CEO, Hession, Neville and Associates; and Tom de Faye, director, international sales and marketing, diesel division, General Motors.
|
